| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,021 | 0,028 | 23:00 | |
| 0,022 | 0,026 | 22:00 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.10. | Hemostemix Inc (2): Hemostemix receives Bahamian OK for VesCell study | 3 | Stockwatch | ||
| 08.10. | Hemostemix Inc (2): Hemostemix 13,645,000-share private placement | 1 | Stockwatch | ||
| 07.10. | Hemostemix Inc.: Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update | 638 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that it has received full approval from the National... ► Artikel lesen | |
| 28.09. | Centurion One Capital Corp.: Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit | 425 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that it is presenting at the Centurion... ► Artikel lesen | |
| 24.09. | Hemostemix Inc (2): Hemostemix closes third tranche of private placement | 1 | Stockwatch | ||
| 23.09. | Hemostemix Inc.: Hemostemix Non Brokered Private Placement | 519 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 23, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is filing a Form 4B to obtain... ► Artikel lesen | |
| HEMOSTEMIX Aktie jetzt für 0€ handeln | |||||
| 21.08. | Hemostemix Inc (2): Hemostemix talks up enrolment to hear Shankle | 3 | Stockwatch | ||
| 20.08. | Hemostemix Inc.: Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell Under LARTA | 674 | Newsfile | Leading cognitive-disorders specialist, Dr. William Shankle, will discuss vascular cognitive impairment, vascular dementia and the proposed clinical trial of VesCell (ACP-01) today at 12:00 EST... ► Artikel lesen | |
| 12.08. | Hemostemix Inc (2): Hemostemix names longevity trial principal investigator | 2 | Stockwatch | ||
| 12.08. | Hemostemix Inc.: Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell Longevity Clinical Trial | 1.058 | Newsfile | Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Prof. Dr.... ► Artikel lesen | |
| 31.07. | Hemostemix Inc (2): Hemostemix closes $322,250 second tranche of placement | 1 | Stockwatch | ||
| 31.07. | Hemostemix Inc.: Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026 | 732 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 30, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the second tranche... ► Artikel lesen | |
| 29.07. | Hemostemix Inc (2): Hemostemix drafts VesCell phase 1 trial protocol | 3 | Stockwatch | ||
| 28.07. | Hemostemix Inc.: Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell's Excellent Results | 726 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous (patient's own stem cells) regenerative... ► Artikel lesen | |
| 23.07. | Hemostemix Inc (2): Hemostemix grants options to buy 6.28 million shares | 6 | Stockwatch | ||
| 22.07. | Hemostemix Inc.: Hemostemix Grants Stock Options | 498 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 22, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock... ► Artikel lesen | |
| 09.07. | Hemostemix Inc (2): Hemostemix files commercialization application | 3 | Stockwatch | ||
| 08.07. | Hemostemix Inc.: Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain | 648 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 8, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company"), the leading autologous (patient's own stem cells) regenerative medicine... ► Artikel lesen | |
| 26.06. | Hemostemix Inc (2): Hemostemix closes $360,000 first tranche of placement | 2 | Stockwatch | ||
| 26.06. | Hemostemix Inc.: Hemostemix Closes $360,000 First Tranche of Private Placement | 475 | Newsfile | Calgary, Alberta--(Newsfile Corp. - June 26, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the first tranche... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 2,750 | -6,34 % | Evotec-Aktie: Gewinn- und Umsatzrekord? | Die Aktie des Hamburger Wirkstoffforschers Evotec bleibt ein spannender, aber risikoreicher Titel am deutschen Aktienmarkt. Nach schwierigen Monaten sorgen erste operative Fortschritte, neue Partnerschaften... ► Artikel lesen | |
| QIAGEN | 45,200 | -0,24 % | QIAGEN N.V.: QIAGEN-Aktionäre stimmen der Berufung von Jonathan M. Pratt in die Geschäftsführung mit überwältigender Mehrheit zu | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass die Aktionärinnen und Aktionäre auf einer Außerordentlichen Hauptversammlung der Berufung von Jonathan M. Pratt... ► Artikel lesen | |
| VALNEVA | 2,559 | -1,20 % | Valneva: Neue Langzeitdaten für Chikungunya-Impfstoff | Valneva hat neue Langzeitdaten zu seinem Chikungunya-Impfstoff IXCHIQ vorgelegt. Fünf Jahre nach einer einmaligen Impfung wiesen noch 94 Prozent der 221 auswertbaren Studienteilnehmer neutralisierende... ► Artikel lesen | |
| EPIGENOMICS | 0,870 | 0,00 % | PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
Epigenomics AG: Veröffentlichung nach -- 40 Abs. 1 WpHG
Heidelberg (pta000/26.10.2026/15:00... ► Artikel lesen | |
| NOVAVAX | 7,200 | -1,77 % | Novavax hebt Prognose an: Worauf es jetzt ankommt | ||
| STRYKER | 288,10 | +1,95 % | Stryker CEO Kevin Lobo says robots now do 2 of every 3 knee replacements-and he won't build them in China because 'the IP is a massive worry' | ||
| CRISPR THERAPEUTICS | 36,550 | -0,42 % | CRISPR Therapeutics Highlights Substantial Lipid Reductions with Investigational Gene Editing Therapy | ||
| CO.DON | 0,005 | -16,67 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| OCUGEN | 0,681 | -3,27 % | Ocugen: Lizenzdeal mit Celairis - wie weit trägt die Aktie jetzt? | ||
| VIKING THERAPEUTICS | 24,600 | +0,82 % | Viking Therapeutics gains amid report of renewed takeover interest | ||
| CG ONCOLOGY | 78,93 | -6,90 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| SUMMIT THERAPEUTICS | 10,660 | -9,81 % | Summit Therapeutics (SMMT) Hits 52-Week Low After FDA Setback | ||
| PRAXIS PRECISION MEDICINES | 305,32 | -1,60 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| ERASCA | 13,900 | -7,95 % | Warum die Erasca-Aktie heute nachgibt: Düstere Verlustprognosen belasten den Kurs | ||
| EDGEWISE THERAPEUTICS | 42,020 | -3,80 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen |